Your Health, We Care
Enasidenib is an isocitrate dehydrogenase-2 inhibitor developed by Celgene Corporation in the United States and approved by the United States Food and Drug Administration (FDA) in 2017.
The FDA emphasizes that early recognition and aggressive management of differentiation syndrome is critical to reduce the risk of exacerbations and death.
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
